title: Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review.
abstract: BACKGROUND
  Many studies evaluated the association of V617F Jak-2 with the risk of thrombosis in patients with essential thrombocythaemia, but the results of these studies were inconsistent. Few studies evaluated the association of V617F Jak-2 mutation with the risk of thrombosis in patients with idiopathic myelofibrosis. Therefore, we performed a systematic review of the studies that assessed the risk of thrombosis associated with V617F Jak-2 in patients with ET or IM.
  
  
  METHODS
  We searched MEDLINE and EMBASE databases and reference lists of retrieved articles. Odds ratios (ORs) and 95% confidence intervals (CI) were calculated for each trial and pooled.
  
  
  RESULTS
  We included 21 studies involving patients with essential thrombocythaemia and 6 studies patients with idiopathic myelofibrosis. In essential thrombocythaemia patients, V617F Jak-2 was associated with a significant increased risk of thrombosis (OR 1.92, 95% CI 1.45-2.53), both of venous (OR 2.49, 95% CI 1.71-3.61) and arterial (OR 1.77, 95% CI 1.29-2.43) vessels. In idiopathic myelofibrosis patients, the risk of thrombosis associated with V617F Jak-2 tended to be increased (OR 1.76, 95% CI 0.91-3.41).
  
  
  CONCLUSIONS
  Our systematic review suggests that V617F Jak-2 increases the risk of thrombosis in essential thrombocythaemia patients by about two fold while its role in idiopathic myelofibrosis patients is uncertain.
authors.affiliation: Divisione di Medicina Generale III, Azienda Ospedaliera San Paolo Dipartimento di Medicina, Chirurgia e Odontoiatria, Università di Milano, Via A. di Rudinì 8, Milan, Italy. federico.lussana@ao-sanpaolo.it
authors.forename: Federico
authors.initials: F
authors.lastname: Lussana
authors.forename: Sabrina
authors.initials: S
authors.lastname: Caberlon
authors.forename: Chiara
authors.initials: C
authors.lastname: Pagani
authors.forename: Pieter W
authors.initials: PW
authors.lastname: Kamphuisen
authors.forename: Harry R
authors.initials: HR
authors.lastname: Büller
authors.forename: Marco
authors.initials: M
authors.lastname: Cattaneo
mesh_terms: D005838:Genotype; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D009154:Mutation / Q000235:genetics*; D055728:Primary Myelofibrosis / Q000150:complications / Q000175:diagnosis / Q000235:genetics*; D012307:Risk Factors; D013920:Thrombocythemia, Essential / Q000150:complications / Q000175:diagnosis / Q000235:genetics*; D013927:Thrombosis / Q000150:complications / Q000175:diagnosis / Q000235:genetics*
chemical_list: C507924:JAK2 protein, human; D053614:Janus Kinase 2